| Bioactivity | Etomidate (R 16659) is a potent GABAA receptor agonist. Etomidate is a neurological drug and effective parenteral medication and has the potential for management of endogenous hypercortisolaemia[1][2]. | ||||||||||||
| Invitro | Etomidate (R 16659) is a potent inhibitor of the adrenal response to surgery. The absence of clinical consequences associated with the blunted response suggests that a major increase in adrenal hormone production may not be necessary during surgery[1]. | ||||||||||||
| Name | Etomidate | ||||||||||||
| CAS | 33125-97-2 | ||||||||||||
| Formula | C14H16N2O2 | ||||||||||||
| Molar Mass | 244.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here? Crit Care, 2012. 16(6): p. 189. [2]. Veronica A Preda, et al. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012 Aug;167(2):137-43. |